Open AccessInvestigation of the Effect of Canagliflozin on the Disposition Index, a Marker of Pancreatic Beta Cell Function, in Patients with Type 2 Diabetes
Author(s) -
Mitsuyoshi Takahara,
Toshihiko Shiraiwa,
Takaaki Matsuoka,
Kaoru Yamamoto,
Yoshifumi Maeno,
Y Shiraiwa,
Yoko Yoshida,
Naoto Katakami,
Hiroaki Iijima,
Hideyuki Katsumata,
Keiichi Akita,
Takeji Hashimoto,
Iichiro Shimomura
Publication year - 2020
Publication title -
diabetes, metabolic syndrome and obesity
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.853
H-Index - 43
ISSN - 1178-7007
DOI - 10.2147/dmso.s273396
Subject(s) - canagliflozin , glimepiride , medicine , hypoglycemia , glycemic , type 2 diabetes , urology , endocrinology , clinical endpoint , metformin , gastroenterology , diabetes mellitus , randomized controlled trial
Our aim was to investigate the effects of add-on canagliflozin with glimepiride dose adjustment or glimepiride dose adjustment on pancreatic beta cell function in patients with type 2 diabetes mellitus and inadequate glycemic control despite stable triple therapy (metformin, teneligliptin, and glimepiride) plus diet/exercise therapy.